"FDA Investigates Weight Loss Drugs Amid Conflicting Reports on Mental Health Risks"

The FDA is investigating reports of hair loss and suicidal thoughts among users of GLP-1 receptor agonists, such as Ozempic, Mounjaro, and Wegovy, which are medications for diabetes and weight loss. While these side effects, along with aspiration, have been reported to the FDA Adverse Event Reporting System, the FDA has not yet established a causal relationship between the drugs and the risks. The FDA's ongoing drug safety monitoring may lead to regulatory actions like label changes or the development of a Risk Evaluation and Mitigation Strategy. Novo Nordisk, the manufacturer of several GLP-1 agonists, emphasizes their commitment to patient safety and the efficacy of their medications when used properly.